OBJECTIVE: HIV-infected women need access to safe and effective contraception. Recent animal and human data suggest that hormonal contraception may accelerate HIV disease progression. METHODS: We compared the incidence of HIV disease progression among antiretroviral therapy-naive women with and without exposure to hormonal contraception at 13 sites in Africa and Asia. Disease progression was defined as becoming eligible for antiretroviral therapy or death. RESULTS: Between 1 August 2002 and 31 December 2007, the MTCT-Plus programs enrolled 7846 women. In total, 4109 (52%) women met eligibility criteria for this analysis and contributed 5911 person-years of follow-up (median follow-up, 379 days; interquartile range, 121-833). At baseline, 3064 (75%) women reported using either no contraception or a nonhormonal method, whereas 823 (20%) reported using implants/injectables and 222 (5%) reported using oral contraceptive pills. The disease progression outcome was met by 944 (29%) women (rate, 18.3/100 woman-years). Neither implants/injectables (adjusted hazard ratio 1.0, 95% confidence interval 0.8-1.1) nor oral contraceptive pills (adjusted hazard ratio 0.8, 95% confidence interval 0.6-1.1) were associated with disease progression. Treating contraceptive method as a time-varying exposure did not change this negative finding. CONCLUSION: This multicountry cohort analysis provides some reassurance that hormonal contraception is not associated with HIV disease progression. Further research is needed to address the contraceptive needs of HIV-infected women.
OBJECTIVE:HIV-infectedwomen need access to safe and effective contraception. Recent animal and human data suggest that hormonal contraception may accelerate HIV disease progression. METHODS: We compared the incidence of HIV disease progression among antiretroviral therapy-naive women with and without exposure to hormonal contraception at 13 sites in Africa and Asia. Disease progression was defined as becoming eligible for antiretroviral therapy or death. RESULTS: Between 1 August 2002 and 31 December 2007, the MTCT-Plus programs enrolled 7846 women. In total, 4109 (52%) women met eligibility criteria for this analysis and contributed 5911 person-years of follow-up (median follow-up, 379 days; interquartile range, 121-833). At baseline, 3064 (75%) women reported using either no contraception or a nonhormonal method, whereas 823 (20%) reported using implants/injectables and 222 (5%) reported using oral contraceptive pills. The disease progression outcome was met by 944 (29%) women (rate, 18.3/100 woman-years). Neither implants/injectables (adjusted hazard ratio 1.0, 95% confidence interval 0.8-1.1) nor oral contraceptive pills (adjusted hazard ratio 0.8, 95% confidence interval 0.6-1.1) were associated with disease progression. Treating contraceptive method as a time-varying exposure did not change this negative finding. CONCLUSION: This multicountry cohort analysis provides some reassurance that hormonal contraception is not associated with HIV disease progression. Further research is needed to address the contraceptive needs of HIV-infectedwomen.
Authors: L Danel; C Vincent; F Rousset; B Klein; R Bataille; M Flacher; B G Durie; J P Revillard Journal: J Steroid Biochem Date: 1988 Impact factor: 4.292
Authors: Helen E Cejtin; Lisa Jacobson; Gayle Springer; D Heather Watts; Alexandra Levine; Ruth Greenblatt; Kathryn Anastos; Howard L Minkoff; Leslie S Massad; Julie B Schmidt Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Kristina Abel; Tracy Rourke; Ding Lu; Kristen Bost; Michael B McChesney; Christopher J Miller Journal: J Infect Dis Date: 2004-09-24 Impact factor: 5.226
Authors: Charles S Morrison; Pai-Lien Chen; Immaculate Nankya; Anne Rinaldi; Barbara Van Der Pol; Yun-Rong Ma; Tsungai Chipato; Roy Mugerwa; Megan Dunbar; Eric Arts; Robert A Salata Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Jessica L Castilho; Cathy A Jenkins; Bryan E Shepherd; Sally S Bebawy; Megan Turner; Timothy R Sterling; Vlada V Melekhin Journal: J Womens Health (Larchmt) Date: 2015-03-09 Impact factor: 2.681
Authors: Maura K Whiteman; Gary Jeng; Anna Samarina; Natalia Akatova; Margarita Martirosyan; Dmitry M Kissin; Kathryn M Curtis; Polly A Marchbanks; Susan D Hillis; Michele G Mandel; Denise J Jamieson Journal: Contraception Date: 2015-07-18 Impact factor: 3.375
Authors: J Saxton; R Malyuta; I Semenenko; T Pilipenko; R Tereshenko; E Kulakovskaya; I Adejnova; L Kvasha; C Thorne Journal: Hum Reprod Date: 2010-07-19 Impact factor: 6.918
Authors: Richard P H Huijbregts; E Scott Helton; Katherine G Michel; Steffanie Sabbaj; Holly E Richter; Paul A Goepfert; Zdenek Hel Journal: Endocrinology Date: 2013-01-25 Impact factor: 4.736